Genitourinary Cancers

Manuela Schmidinger, MD, medical oncologist, Medical University of Vienna, discusses the management of side effects from targeted therapies in renal cell carcinoma (RCC).

An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer.

Viktor Grünwald, MD, PhD, an attending physician at the Hannover Medical School, discusses tumor remission in patients with renal cell carcinoma (RCC).

Daniel J. George, MD, director, GU Oncology, Duke Cancer Institute, discusses the use of sunitinib to treat patients with renal cell carcinoma (RCC).

The American Cancer Society estimates that in 2013, 142,820 individuals in the United States will be diagnosed with colorectal cancer and 72,570 with bladder cancer

USO co-founders John Forrest, MD, and Robert Bruce, MD, have known each other since the fourth grade. They both attended medical school at the University of Oklahoma and, after some time away from home, ultimately joined two different, well-established practices in north and south Tulsa.

Dovitinib failed to meet the primary endpoint of improving progression-free survival versus sorafenib (Nexavar) in patients with heavily pretreated progressive renal cell carcinoma

Manuela Schmidinger, MD, medical oncologist, Medical University of Vienna, discusses the management of side effects from targeted agents in renal cell cancer, including hypertension, diarrhea, and hand-foot syndrome.

Viktor Grünwald, MD, PhD, from the Hannover Medical School, discusses a phase III trial that compared dovitinib to sorafenib for patients with mRCC following prior treatment with one VEGF inhibitor and one mTOR inhibitor.

Daniel J. George, MD, Director, GU Oncology, Duke Cancer Institute, discusses critical phase III clinical trials in metastatic renal cell carcinoma.

Marijuana users had a small but statistically lower risk of bladder cancer compared with people who smoked tobacco or did not smoke.

The standard of care for metastatic renal cell carcinoma (RCC) prevailed in a randomized comparison of everolimus (Afinitor) and sunitinib (Sutent) as first-line therapy

Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherpay Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses how immunotherapies work in patients with melanoma or renal cancer.

Patients with advanced renal cell carcinoma could experience a greater quality of life and the same treatment benefit with pazopanib as opposed to sunitinib.

Change may not always be pleasant, but it is inevitable, and nowhere has that been more evident recently than in US healthcare; however, for the physicians at Regional Urology in Shreveport, Louisiana, these changes are really just business as usual.

We should move away from directing therapy based on the primary site of malignancy and focus our efforts on inherent pathways common to the tumors, irrespective of the organ.

Nivolumab, the most advanced agent in the rapidly developing field of PD-1-targeting cancer immunotherapy, delivered durable clinical benefits across multiple solid tumor types.

Preoperative chemotherapy was not a predictor of postoperative complications, nor did it increase the length of hospital stays or surgical complications among patients undergoing radical cystectomy for muscle-invasive bladder cancer.

Current T staging for renal cell carcinoma does not capture the full picture of tumor volume, which data have shown to be more predictive of survival and recurrence in certain types of cancer.

An assay based on tumor genetics showed potential for stratifying risk in prostate cancer patients and aiding selection of men for active surveillance.